
TBPH Stock Forecast & Price Target
TBPH Analyst Ratings
Bulls say
Theravance Biopharma is expected to see increased value through its acquisition by Zymeworks, which will likely result in a boost to the company's share price. Their YUPELRI product continues to perform well, with increasing sales and strong margins, and their IP has been secured through 2039. The company is also restructuring, which is expected to lead to further improvements in cash flow.
Bears say
Theravance Biopharma is currently facing several challenges, including the failure of its Phase 3 clinical study for ampreloxetine, competition in the market for its FDA-approved medicine YUPELRI, and potential financial risks due to its restructuring efforts. Additionally, the company's ongoing strategic review process and potential sale could also negatively impact its stock value and cash position in the near term.
This aggregate rating is based on analysts' research of Theravance Biopharma Inc and is not a guaranteed prediction by Public.com or investment advice.
TBPH Analyst Forecast & Price Prediction
Start investing in TBPH
Order type
Buy in
Order amount
Est. shares
0 shares